RedHill Biopharma to Vote on CEO Dror Ben-Asher Also Serving as Chairman of the Board
RDHL is trading near its 52-week low of $0.71 (12% above the low) on elevated volume (3.4× avg).
Summary
RedHill Biopharma will hold its Annual General Meeting to re-elect directors, re-appoint auditors, and approve CEO Dror Ben-Asher also serving as Chairman of the Board.
Key Events · Corporate Governance and Compliance · RDHL
-
Leadership Consolidation Proposed
Shareholders will vote on approving current CEO Dror Ben-Asher to also serve as the Company's Chairman of the Board of Directors.
-
Director Re-election
Mr. Rick D. Scruggs and Dr. Shmuel Cabilly are proposed for re-election to the board for an additional three-year term.
-
Auditor Re-appointment
Kesselman & Kesselman is proposed for re-appointment as the Company's auditors for the year 2026.
Analysis · RDHL · Life Sciences
This Annual General Meeting includes a significant corporate governance proposal to appoint current CEO Dror Ben-Asher as Chairman of the Board. This consolidation of leadership comes at a critical time for RedHill Biopharma, which recently announced a substantial $19.4 million private placement and is navigating a Nasdaq delisting notice and a 'going concern' warning. Unified leadership could be seen as beneficial for decisive action during this challenging period.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1963 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.14%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDHL was trading at $0.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.71 to $3.31. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.